Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TB-007
- Development stage
- Preclinical
- Lead developer
- ThinkingBiomed
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TB-007 is an investigational, universal off-the-shelf cell therapy being developed by ThinkingBiomed (昕传生物) for the treatment of solid tumors. It utilizes the company's proprietary CAR-INK platform, which involves engineering a variant of Natural Killer (NK) cells—referred to as "INK" cells—with a Chimeric Antigen Receptor (CAR) to enhance tumor-specific targeting and cytotoxicity. As a universal, off-the-shelf product, TB-007 is designed to be produced at scale and administered to patients without the need for individualized manufacturing. The program is currently in the early research and preclinical validation stage, targeting a broad range of solid tumors.
- Other names
- TB-007 CAR-INKTB007 CAR-INKTB 007 CAR-INK
Beyond the preview
Go deeper on TB-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TB-007.